Accelerated long-term forgetting: from subjective memory decline to a defined clinical entity

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2024 Feb 16:1-12. doi: 10.1080/13825585.2024.2317924. Online ahead of print.

Abstract

Subjective memory decline (SMD) might represent the preclinical phase of Alzheimer's disease (AD), and has been reported in epileptic amnesia associated with accelerated long-term forgetting (ALF). We investigated ALF in SMD subjects by means of RAVLT recall and recognition and ROCF recall after 1-week retention and compared with a control group. Two-way ANOVAs for RAVLT and ROCF were conducted, and stepwise regression analysis was administered considering EMQ and DASS-21 as factors. SMD subjects performed significantly worse than controls at 1-week delay on RAVLT recall and recognition, but not on ROCF, and not associated with depression or memory complaints. SMD patients showed ALF, which is usually associated with temporomesial dysfunctions, representing a cognitive marker to assess objectively memory problems in SMD, and to undisclose initial neurodegenerative disease involving temporal structures usually compromised in AD. Therefore, SMD might no longer be "subjective," but rather a specific and defined clinical entity.

Keywords: Alzheimer’s disease; Subjective memory decline; accelerated long-term forgetting; amnesia; epilepsy.